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1. Introduction—Receptor Function
To achieve success in the competition for favorable
chemical and physical conditions, all organisms (from bacteria
to worms to humans) must rapidly and accurately sense
changes in their environments. Likewise, the complex orches-
trations that govern developmental patterning or immuno-
logical responses rely on communication between cells and
their environs. The task of monitoring extracellular conditions
falls to the cell-surface receptors. These proteins coordinate
the cells internal machinery by collecting, compiling, and
translating external information. The pressure for survival
demands that responses to stimuli be sensitive and accurate;
synergistic and competitive signals must be amplified and
integrated. Thus, cells have developed sophisticated and
elegant methods for achieving sensitive yet controllable
receptor-mediated responses.
One important mechanism for efficient and sensitive
signaling is to couple the functions of multiple cell-surface
receptors,[1–9] most of which do not typically operate as
individual entities, but function in concert. An emerging
paradigm is that receptors within multireceptor signaling
complexes communicate with each other.[7] Although evi-
dence is mounting for communication between receptors, an
understanding of the underlying mechanisms is elusive.
Chemical synthesis can provide a variety of compounds
with which to address the role of receptor assembly in signal
transduction. Multivalent ligands are well-suited to this task.
They are capable of illuminating aspects of interreceptor
processes that are not readily probed by using conventional
approaches. We suggest that, as the focus shifts from
investigations of the function of individual proteins toward
the analysis of multireceptor signaling complexes, multivalent
ligands will become even more valuable tools to probe
sophisticated mechanistic questions. Moreover, multivalent
ligands may provide new opportunities for manipulating
receptor systems to dissect pathways and, ultimately, treat
diseases. This Review focuses on the role of synthetic
multivalent ligands as probes for the investigation of receptor
collaboration.
2. Direct and Indirect Interactions between
Receptors
2.1. Signaling Complexes
Receptors transmit information on extracellular signals to
the internal machinery of the cell. Different receptors often
share common cytoplasmic components, and therefore infor-
mation transfer must be constrained to prevent unwanted
exchange between disparate pathways.[7,10–12] To understand
how signals are transmitted, it is necessary to unravel how
cells can respond distinctly to different stimuli by using a set
of common components.[7]
The subcellular localization of receptors into signaling
complexes is proposed to be one mechanism by which cells
achieve spatial and temporal regulation.[13–19] Multiprotein
signaling complexes constitute the principle signaling units of
neuronal synapses,[20, 21] immune synapses,[13,22, 23] focal adhe-
sions,[24] and bacterial chemoreceptor arrays (Figure 1).[25,26]
Cell-surface receptors acquire information from the extracellular
environment and coordinate intracellular responses. Many receptors
do not operate as individual entities, but rather as part of dimeric or
oligomeric complexes. Coupling the functions of multiple receptors
may endow signaling pathways with the sensitivity and malleability
required to govern cellular responses. Moreover, multireceptor
signaling complexes may provide a means of spatially segregating
otherwise degenerate signaling cascades. Understanding the mecha-
nisms, extent, and consequences of receptor co-localization and
interreceptor communication is critical; chemical synthesis can
provide compounds to address the role of receptor assembly in signal
transduction. Multivalent ligands can be generated that possess a
variety of sizes, shapes, valencies, orientations, and densities of binding
elements. This Review focuses on the use of synthetic multivalent
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These ensembles are composed of receptors, signaling
proteins, adapter proteins, and cytoskeletal components.[27–29]
Many signaling complexes in eukaryotic cells appear to be
associated with detergent-insoluble lipid microdomains that
provide unique physical environments for the concentration
of signaling components.[30–35] Often it is not known whether
cells use microdomains or other mechanisms to organize and
assemble signaling components.
The formation of signaling complexes is not restricted to
any particular receptor class. Data from microscopy, covalent
cross-linking, and X-ray crystallography experiments have
revealed that cell-surface receptors from many structural
classes assemble into multireceptor complexes; these include
some heptahelical G-protein-coupled receptors
(GPCRs),[36–38] methyl-accepting chemotaxis proteins
(MCPs),[39] gated ion channels,[40] receptor-protein tyrosine
kinases (RPTKs),[41,42] and multichain immune recognition
receptors (MIRRs).[22, 33,35, 43–45] The size of these ensembles
varies: Some complexes are composed of two receptors while
others contain thousands. Some receptors,[46–48] including the
ryanodine receptor[40] and MCPs,[39] are so highly concen-
trated that they dominate certain cellular regions. Unfortu-
nately, little is known about the structures of these assemblies,
where they are localized within the cells, and how their
localization influences signaling. Understanding these issues,
however, could lead to new strategies to precisely control
receptor function and therefore cellular responses. Although
there remains a need to explore the role of receptor local-
ization and assembly, the data acquired to date suggest some
general basic principles for communication between the
receptors.
Receptors can exchange information through direct
protein–protein contacts or through intermediary proteins.
Direct receptor contact typically involves interactions
between specific protein regions.[49] For example, helix-
mediated interactions are proposed to facilitate the dimeri-
zation and oligomerization of GPCRs (Figure 2).[38, 50,51]
Evidence for the functional importance of these interactions
is suggested by engineering disrupting mutations in the
proposed contact sites or by adding isolated transmembrane
helices to GPCRs.[37, 52,53] Although their effects on receptor
oligomerization are not yet well-established, these manipu-
lations modulate signaling; presumably, they disrupt recep-
tor–receptor contacts. As mentioned above, an alternative
strategy by which receptors exchange information is through
intermediary proteins. These scaffolding proteins can organ-
ize multireceptor complexes, and thus act as frameworks for
protein assembly. Examples of receptors localized by this
mechanism include the MCPs and members of the tumor
necrosis factor (TNF) receptors (Figure 2 B, C).[54–56]
Ligand binding can transduce signals by directly stabiliz-
ing or destabilizing protein assemblies.[57–59] For example, data
collected from diverse experiments suggest that binding of an
attractant to a single MCP can elicit signaling from nearby
MCP partners.[46, 60–64] Similarly, cross-phosphorylation of
some growth-factor receptors is facilitated by ligand-induced
contacts.[65] In addition to homodimeric (or oligomeric)
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Figure 1. Examples of complexes involved in signal transduction:
A) eukaryotic immune recognition; B) eukaryotic cell adhesion; C) pro-
karyotic chemotaxis; and D) neuronal signaling. These schematic
depictions simplify the complexity of biological multiprotein signaling
complexes.
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interactions, interactions between structurally dissimilar
receptors have also been demonstrated.[66] The neuronal
dopamine and GABA receptors, a gated ion channel, and a
GPCR, have been shown to exchange information by direct
contact.[67]
An alternative means by which ligands can induce
information transfer and co-localization of receptors is by
facilitating the recruitment of intermediary proteins to the
target receptors; these intermediary proteins are called
adapters or scaffolding proteins.[68–73] Specialized modules
within intermediary proteins act as information conduits;
examples include SH2, SH3, and PDZ domains. These
domains participate in a series of protein–protein interactions
that transfer information and localize receptors. The simplest
adapters directly link one receptor to another. Additionally,
many intermediary proteins contain multiple domains that
facilitate communication between a receptor and a variety of
membrane-associated and soluble signaling proteins.
2.2. Factors that Influence Communication between Receptors
An important first step in investigating and manipulating
the function of a multireceptor signaling complex is defining
the features. However, the potential diversity created by the
presence of multiple receptors and modular adapters raises
challenges for those that seek to understand them. The
features of the immune synapse illustrate some of the
issues relevant for elucidating the function of signaling
complexes.
T lymphocytes are critical mediators of effective immune
responses to invading pathogens. The contribution of T cells
to the immune response is largely controlled by signaling
through the T-cell receptor (TCR). Like many other impor-
tant cell-surface receptors, the TCR can be assembled into a
multireceptor complex. When a T cell contacts an antigen-
presenting cell (namely, a dendritic or B cell), the cytoskele-
ton reorganizes, and adhesion receptors and the TCR
undergo changes in localization at the interface. This interface
has been referred to as the “immune synapse” (Figure 1A).
The features of the immune synapse can vary. Its structure
is influenced by the type of antigen-presenting cell (APC)
involved, the type and activation state of the T cell, the
duration of the T cell/APC interaction, and the local physio-
logical environment in which it forms.[74] Powerful new
imaging methods have been used to visualize immune
synapses formed in vitro and in vivo; these studies reveal
that dynamic changes in protein localization and organization
can occur. At a molecular level, the role of protein
organization within the synapse has not yet been established.
It is not known whether the observed organization of the
receptors on the T cell influences signaling.
It is clear that the TCR[75] and co-receptors, such as
CD4,[76, 77] are localized at the cell–cell interface. Some of
these co-receptors (for example, CD4) augment the signal
generated by the TCR; others attenuate it. The balance and
orientation of these co-receptors can therefore tune the level
of T-cell activation. This tuning is achieved by changes in the
phosphorylation of intracellular protein domains and recep-
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Figure 2. Proposed multireceptor assemblies for some receptors.
A) Models of three heptahelical GPCR dimers and a trimer based on
mutagenesis results and the structure of bacteriorhodopsin. Each
numbered circle represents a transmembrane helix. A variety of 1–7,
5–6, and 2–3 dimers and multimers have been proposed. B) Bacterial
chemoreceptors (methyl-accepting chemotaxis proteins, MCPs) are
dimeric. These can assemble into a trimer-of-dimers, which can further
interact with signaling proteins, such as the kinase CheA. Each MCP
passes through the membrane twice (1 and 2) and coiled-coil
interactions between these transmembrane domains (1 and 1’) medi-
ate dimerization. A lattice model of MCP organization constructed of
six of these trimers-of-dimers and 24 copies of CheA is shown. C) The
Fas–FasL interaction has been modeled using protein interfaces
suggested by mutagenesis and cross-linking studies. Both the receptor
Fas and its corresponding ligand FasL are trimers. The corresponding
trimeric complex may be employed as a unit in the lattice stabilized by
the adapter protein FADD. Two models are shown with either Fas- or
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tors; the immune synapse also contains kinases such as Lck
and ZAP-70 that catalyze the phosphorylation of ligated
receptors and other proteins.[77,78] Phosphorylation can have
either a positive or negative impact on the subsequent
recruitment or the enzymatic activity of various components
of the signaling complex.
Evidence from microscopy and signaling experiments
suggests that the immune synapse can be highly organized.[76]
The cytoskeleton plays a critical role in organizing some cell-
surface proteins, thus the findings that cytoskeletal compo-
nents are critical for TCR signaling supports a role for
receptor organization.[13,79, 80] The positioning of proteins
within the immune synapse is also highly dynamic. For
example, when a T cell engages with a cell presenting an
antigen, the negative regulator CD45 moves to the periphery
of the synapse.[76, 81–83] Under these circumstances, the TCR is
recruited into the inner portion of the synapse. These changes
in receptor positioning suggest that synapse organization
affects signal transmission: These intricate, orchestrated[76]
movements are believed to affect the transfer and propaga-
tion of the activating signal. The position of the TCR in
relation to the various positive and negative regulators of its
function appears to determine the signal intensity.
There are many parameters that can affect signal output,
and dissecting the contribution of different factors to T-cell
signaling is complicated. Factors that have been proposed to
influence signal output[20] include the number of activated
receptors, their identity, and stoichiometric ratio
(Figure 3).[4, 84,85] The stoichiometric composition of a signal-
ing complex (that is, the number of activating versus damp-
ening receptors) can influence the signal strength required to
overcome thresholds. In addition to the identity and stoichio-
metric composition of receptors in the complex, signaling can
also be influenced by the proximity and subcellular compart-
mentalization of receptors. Determining the relative contri-
bution of all of the aforementioned variables remains a major
challenge. To isolate and dissect such a complex signaling
system a variety of biological and chemical methods are
required. Multivalent ligands are valuable tools in the
armamentarium.
2.3. Challenges in Studying Receptor Function
Historically, cellular functions have been investigated by
detailed examination of the structure and activity of a single
protein component within a reaction pathway. Signal trans-
duction involves the coordinated interactions of many differ-
ent proteins. Thus, understanding cellular functions requires
uncovering how heterogeneous collections of proteins inter-
act at a supramolecular level. Advances in genomics, trans-
genic animal technologies, and chemical biology provide the
means to identify components of a pathway. Elucidating the
functional and structural relationships between these compo-
nents remains a major challenge.[86–88] Even after evidence for
physical association has been obtained, the order in which
these interactions occur and their kinetics must be explored.
Strategies that provide insight into complex cellular processes
are needed.
Understanding multireceptor assemblies requires the use
of methods that reveal both molecular and supramolecular
detail. For example, immunoprecipitation, confocal micro-
scopy, and FIrster resonance energy transfer (FRET) experi-
ments have been influential in exploring changes in subcel-
lular protein distributions.[89,90] Moreover, fluorescent pro-
teins and advanced imaging techniques have revolutionized
the ability to follow proteins in live cells in real time.[91–93]
Although these approaches provide insight into the opera-
tions of multiprotein complexes, the molecular details that








Figure 3. Possible methods for regulating interreceptor communica-
tion. A) The distance can influence the transfer of information between
receptors or other proteins. B) The relative orientation of two receptors
can influence the alignment of enzyme active sites and govern the
rates of covalent modifications that result in signal generation. C) The
number of receptors in a complex can influence the intensity of a
signal. Additionally, the likelihood that receptors will come into contact
increases when the numbers of localized receptors is greater. D) The
subcellular location of a receptor controls the access of some intra-
cellular signaling proteins to the receptor. Changes in position can
govern the flow of information through a receptor or cluster of
receptors. E) Ligand binding can lead to activation of receptors by
separation when co-receptors act as negative regulators. This receptor
mechanism is conceptually related to proximity-induced activation, but
the underlying molecular interactions are quite different.
L. L. Kiessling et al.Reviews
2352 www.angewandte.org  2006 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim Angew. Chem. Int. Ed. 2006, 45, 2348 – 2368
limited understanding arises from an old problem: the details
revealed by an experiment are limited by the resolution of the
investigative methods. For example, the optical resolution of
light microscopy is approximately 200 nm. Fluorescence
microscopy experiments, therefore, can be used to discern
whether receptors are moving from one side of a cell to
another, but information concerning the orientation of two
adjacent receptors is more difficult to obtain.
Methods with superior resolution are required for inves-
tigating receptor–receptor interactions that occur over sub-
nanometer distances. Although FRET can be used to inves-
tigate receptor assembly at this level, its application typically
requires that cell lines be engineered to produce fluorescent
proteins. Electron microscopy, which does not require trans-
fected cell lines, has a limit of resolution of approximately
0.1 nm; thus, it reveals features that are 1000-fold smaller than
those observed by optical microscopy. More recently, advan-
ces in single-particle methods have started to provide
molecular detail for some signaling complexes.[45,92–94] These
advances in experimental methodology provide a framework
from which to develop reagents for studying the function of
multireceptor complexes.
New methods for exploring receptor signaling also are
emerging from synthetic organic chemistry and chemical
biology. Chemical synthesis provides access to unique com-
pounds that can be used to dissect the role of molecular
interactions. These ligands, in concert with the new imaging
techniques, can illuminate the roles of protein assemblies.
This Review focuses on the application of synthetic multi-
valent ligands to the analysis of signaling complexes.[9, 84]
3.Multivalent Ligands as Probes for Receptor–
Receptor Interactions
3.1.Multivalent Ligand Structure and Function
Multivalent ligands present multiple copies of a recog-
nition element (RE) from a central scaffold.[84,95–98] The REs
of a multivalent ligand can be a carbohydrate, peptide,
protein, or small molecule—any moiety that binds to a
receptor. The scaffold determines the structural features of
the multivalent ligand; it also dictates how easily they can be
varied. These issues are relevant because the architecture of a
multivalent ligand—its shape, orientation of the REs, flexi-
bility, size, valency—can influence its biological activity and
its mechanism of action.[99–101] For example, in systems that are
activated by receptor clustering, the most potent ligands may
be those with many, closely spaced REs. Ligands with defined
features and tailored biological activities can be attained by
chemical synthesis.
An important concept underlies the design of multivalent
ligands that activate cellular signaling: many cell-surface
receptors are modular. For example, some receptors possess
intracellular catalytic domains, which are distinct from their
extracellular binding domains; the RE-binding and signal-
generating regions of receptors are therefore structurally and
spatially distinct. Thus, multivalent binding to sites at the
surface of the cell can be used to assemble and thereby
influence interactions of distal intracellular (cytoplasmic)
components. This situation is distinct from that encountered
using typical catalysts for organic reactions, in which the
formation of the catalyst–substrate complex results in a
chemical transformation. Thus, substrate binding and cata-
lytic activity are inextricably linked. Since binding and
catalytic activity are separated for most cell-surface receptors,
multivalent ligands can be used to manipulate the localization
of intracellular catalytic domains. Ligand binding can pro-
mote changes in the receptor and therefore the catalyst
environment which can enhance or restrict access of a
substrate to the catalytic domain. In this way, a multivalent
ligand can influence cellular responses.
As a result of the way in which they function, the
nomenclature used to describe the activities of monovalent
compounds can lead to confusion.[102] Bioactive and mono-
valent compounds are often referred to as agonists or
antagonists: The former activates a response, while the
latter inhibits it. There is often a mechanistic implication in
the use of these terms—agonists are believed to induce a
conformational change similar to that of the natural ligand,
but antagonists induce an inactive conformation. It is these
mechanistic implications that complicate the use of this
nomenclature to describe multivalent ligands. An individual
RE, for example, can be an agonist, partial agonist, or
antagonist. Unlike a single RE, however, the ability of a
multivalent ligand to activate or inhibit a biological response
will be influenced not only by the RE itself but also by the
architecture of the scaffold upon which it is displayed. A
multivalent display of an RE that serves as a monovalent
antagonist, for example, may lead to clustering of receptors;
thus, the multivalent ligand could serve as an agonist.[103]
Likewise, a multivalent ligand composed of REs that bind
to a site remote from that of the physiological ligand can
induce activation of some systems solely by decreasing the
distances between the receptors.[104, 105] Conversely, it has been
proposed that multiple agonistic REs displayed in an
orientation that holds receptors in unproductive arrange-
ments for signaling can result in a multivalent antago-
nist.[106,107] Ligand-induced sequestering of key signaling
proteins also can cause antagonist- or agonist-like
effects.[108,109] Thus, instead of terming multivalent ligands
agonists or antagonists, we refer to them as either multivalent
effectors or inhibitors.[84] Inhibitors block receptor function
and multivalent effectors activate cellular processes. This
terminology does not imply any particular activity for an
individual recognition element nor a specific binding mode; it
is a function of both the RE identity and the architecture of
the multivalent ligand.
3.2.Multivalent Ligand Architectures
A variety of natural, synthetic, and semisynthetic scaffolds
have been used to probe receptor function (see Figure 4 for
examples). These scaffolds vary in size, shape, and physical
characteristics. Different scaffolds display REs differently
(see Section 3.1); therefore, the structure of a scaffold can




2353Angew. Chem. Int. Ed. 2006, 45, 2348 – 2368  2006 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
scaffold, such as a protein or dendrimer, may not be capable
of spanning the large distances needed to cluster multiple
proteins, but may effectively occupy multiple binding sites on
an oligomeric receptor. Thus, the architecture of a ligand
influences its ability to form different types of macromolec-
ular receptor complexes.[84, 100,110]
It is useful to examine the structural complexity of natural
multivalent ligands to understand how to design synthetic
multivalent ligands. The architectures of natural ligands are
enormously diverse. For example, the TNF family member
sTALL was found to be an ensemble of 60 monomer units
that interact noncovalently to generate a symmetric “virus-
like” complex.[94,111, 112] It is hypothesized that the complex
architecture of sTALL is required to organize multiple copies
of its cell-surface receptor into an active signaling complex.
Other natural ligands, such as lipopolysaccharides, mucins,
and glycosaminoglycans, present a heterogeneous display of
potential receptor binding sites, even within the same
molecule.[113,114] A visual comparison between the architecture
of sTALL and a typical glycosaminoglycan will reveal very
few similarities in either size, shape, or RE density. However,
despite their dramatic structural differences, both sTALL and
glycosaminoglycans are involved in clustering cell-surface
receptors. This simple observation can prompt hypotheses
about how differences in the scaffold architecture might have
an impact on the underlying signaling process. Often, how-
ever, it is difficult to determine which of the many possible
ligand features influence activity. For example, naturally
occurring polysaccharides vary in length, branching, and
monosaccharide composition. Tracing the specific feature of a
physiological multivalent ligand that is critical for activity can
be arduous.
Synthetic organic chemistry can provide a wide range of
defined multivalent ligand architectures. This diversity means
that synthetic ligands can be used to dissect the features of
physiological ligands that are responsible for their activity.
For example, unlike natural ligands, the valency of a synthetic
ligand can be systematically altered by varying the length or
size of the scaffold. The effect of valency on the activity can be
assessed by generating polymers of defined lengths. Similarly,
the effect of dendrimer valency on activity can be explored by
testing different generations. Examining the impact of these
changes on the biological response illuminates the mecha-
nisms underlying the function of natural receptor–ligand
complexes to be illuminated. In the following sections we
briefly introduce the synthesis and application of some
structural classes of multivalent ligands. Finally, we discuss
how synthetic multivalent ligands have been used to elucidate
and exploit the mechanisms by which key receptors function.
3.3. Synthesis of Multivalent Ligands
The most versatile methods for synthesizing multivalent
ligands involve adding REs to a preformed synthetic or
naturally occurring scaffold. Scaffolds have been used from
many structure classes: proteins, dendrimers, polymers, and
solid supports.[115] With an appropriately functionalized scaf-
fold (or RE), multiple copies of an RE can be appended. This
approach provides straightforward access to ligands with
variable valency and density of REs, since the mole fraction of
functionalized RE used in the conjugation reaction can be
readily controlled.[115] An alternative to this strategy is the
approach typically used in creating polymer-based multi-
valent ligands: A single step can be used to assemble RE-
bearing monomers into a multivalent product.
In most of the examples presented herein, the REs have
been added to a preformed scaffold to generate the multi-
valent ligands. The examples that we discuss can guide the
selection of scaffold; the corresponding literature references
can be used to design the most efficient synthetic route.
3.3.1. Low-Molecular-Weight Ligands
We use the descriptor “low-molecular-weight ligands” to
refer to compounds that present fewer than ten REs and are
typically less than 1000 Da. The synthesis of such compounds
can be quite challenging; however, some general strategies
have been developed.[116–119] Although methods for the direct
dimerization of individual REs are known,[119] low-molecular-
weight multivalent ligands are typically generated by con-
jugation of REs to a core scaffold. An advantage of these
ligands is that the core scaffold can be rigid to give rise to a
specific orientation of the REs. Additionally, low-molecular-
weight ligands can be generated by combinatorial
approaches,[120,121] therefore allowing their shape, flexibility,








Figure 4. Scaled diagram of the scaffold structures of multivalent ligands.
The boxes show a size comparison of the ligands to a mammalian
lymphocyte. Size bars are as follows: cell and bead 1 mm; liposome and
polymer 0.5 mm; antibody, dendrimer, and albumin 0.05 mm. The immuno-
globulin structure is based on PDB1IGT and the albumin is human serum
albumin from PDB1BM0. The beads are reproduced with permission from
reference [262]. The liposomes are courtesy of A. Menon, the cell is a
cultured Jurkat cell,[263] the dendrimer model was generated at the Caltech
Molecular and Process Simulation Center, and the ROMP-derived polymer
was designed by C. W. Cairo (unpublished results).
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opportunities to exert precise control over ligand features,
most low-molecular-weight ligands are dimeric. Dimeric
ligands can be more readily synthesized but can interact
with only two cell-surface receptors; thus their utility for
investigating the role of higher order receptor organization in
signaling is limited.
3.3.2. Protein Conjugates
Semisynthetic routes to multivalent ligands often involve
the incorporation of REs onto well-characterized carrier
proteins such as streptavidin, bovine serum albumin (BSA),
and keyhole limpet hemocyanin (KLH).[122,123] The size and
shape of the scaffolds vary: the tetrameric streptavidin has a
rectangular structure with dimensions of approximately
6 nm K 10 nm, while human serum albumin has a globular
shape with a diameter of approximately 10 nm. The drawback
of protein conjugates and other multivalent compounds
generated by semisynthesis is their relative heterogeneity
compared to scaffolds generated by chemical synthesis.
Protein conjugation reactions typically depend on the pres-
ence and accessibility of specific endogenous amino acid side
chains. Thus, the opportunities for controlling the orientation
of the epitope are limited. Interestingly, this limitation has
been partially overcome recently by introducing functionality
to viral coat proteins. Viral particles bearing these modified
proteins organize the functionality in defined patterns.[124–126]
This is a promising strategy that is just beginning to be
explored, and the scope of its application is not yet known.
3.3.3. Solid Supports
Receptor binding, activation, and endocytosis have been
studied using functionalized beads and surfaces.[127–130] The
beads employed in these investigations vary in composition:
they can be derived from polystyrene, latex, polysaccharides,
or other insoluble materials. The typical reactions used to
conjugate binding epitopes to beads are straightforward and
general, although rarely chemoselective or regioselective. A
variety of small and large synthetic and natural REs have
been incorporated. The number of potential sites that can be
functionalized on the surface varies with the bead composi-
tion. Although beads are widely used, the orientation and
availability of their binding sites has not been characterized;
generally, the distribution of sites on the bead (and perhaps
on the RE) is assumed to be random. Bead size is another
variable that can influence bead activity. Indeed, the diameter
of the beads can vary widely. For example, sepharose beads,
which are used for size-exclusion chromatography, have
diameters of 30 to 300 mm; latex beads, with diameters of
0.2 to 2 mm, are much smaller. The number of receptors that a
functionalized bead can occupy will depend on many
variables: the number of functional REs presented, the
density of RE sites, and the size of the beads. The only
variable that can be controlled readily is the size of the beads.
As with protein scaffolds, a drawback of the beads is the lack
of control they offer.
3.3.4. Liposomes
Liposomes are typically noncovalent assemblies that can
be used to present multiple REs. It is the lipid–lipid
interactions that give rise to the array;[131–133] thus, liposome
composition can be controlled by varying the ratio of RE-
bearing and unmodified lipids. Liposomes can be generated in
a wide range of sizes. For example, liposomes generated by
treatment with biobeads affords species with diameters of
0.05 to 0.5 mm.[134] Large liposomes (termed giant vesicles)
with diameters of 5–200 mm can also be produced.[135] The size
of the liposomes can be nearly homogeneous; however, the
arrangement of REs within each liposome is difficult to
regulate. Fluctuations in RE presentation within a liposome
can be an advantage in generating RE displays that are highly
active. The orientation and density of REs can change as the
lipid components undergo two-dimensional diffusion; thus
allowing the most active arrangement of REs to be found.
This dynamic behavior is detrimental for mechanistic studies.
Another potential drawback of liposomes is that individual
components can partition into biological membranes; there-
fore, the use of liposomes can be problematic for mechanistic
studies involving organisms or even cells.
3.3.5. Dendrimers
Dendrimers are often used as multivalent ligand scaf-
folds.[96, 136–141] These ligands can be fairly homogeneous,[96]
which can aid in relating ligand features to biological activity.
Beads and carrier–protein conjugates often form heteroge-
neous populations of conjugates since the sites of RE
conjugation are often unknown. In contrast, the architectural
features of a dendrimeric ligand are defined by the choice of
scaffold and the methods used for its synthesis. For example,
starburst (PAMAM) dendrimers of generation 0 have diam-
eters of 1.5 nm and valencies of four.[142] Each increase in
generation increases the diameter by 0.7 to 1.6 nm while also
doubling the maximum valency. Thus, as the size of the
dendrimer increases, so does the RE density. Some of the REs
of such highly functionalized dendrimers can be inaccessible
to proteins.
3.3.6. Polymers
Modern polymer chemistry is providing new opportuni-
ties for the synthesis of tailored, biologically active polymeric
(or oligomeric) ligands. The multivalent ligands derived from
polymers are typically composed of a central backbone that
presents multiple copies of an RE. Ligands of this type can be
produced by using a variety of synthetic methods. Polymers
are generally assembled in a single step by methods such as
radical, ionic, or ring-opening metathesis polymerization of
RE-bearing monomers.[101,143–149] Alternatively, REs can be
appended to a preformed polymeric scaffold.[101,147] Certain
polymerization reactions are more tolerant of biologically
active functionality than others; thus, the type of epitopes to
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Selective polymerization reactions enable the biologically
active ligand to be synthesized with controlled valency.[84]
Living polymerization reactions, in which the rates of chain
termination are low, are powerful methods for generating
well-defined multivalent ligands. Polymers of narrow poly-
dispersity can be generated when the polymerizations have
fast initiation and slow propagation rates.[150] Such polymer-
ization reactions can be used to synthesize multivalent ligands
with a variety of sizes. For example, linear polymers with
molecular weights of approximately 3000 generated by ring-
opening metathesis polymerization (ROMP) can span
100 nm.[151] Polymers displaying dendrimeric appendages
can reach lengths of 10 to 100 nm.[152] In addition to allowing
control over the degree of polymerization, living polymeri-
zation reactions can be used to synthesize block copolymers
that display different REs (or simply different functionality)
within each block.[153]
Polymers generated by ROMP have found increasing use
as biologically active multivalent ligands.[101,149, 154–158] Ruthe-
nium–carbene catalysts for ROMP can be used to generate
materials of distinct valency.[150,159–161] These ligands have been
generated as inhibitors of saccharide–protein interac-
tions,[151, 162–164] as ligands for combating vancomycin-resistant
bacteria,[156] and as effectors of biological responses.[46,165]
Importantly, this polymerization method allows control over
the display and density of REs.[166, 167] The differences in
activity between these compounds can, therefore, be attrib-
uted to specific aspects of ligand structure.
3.3.7. Combinatorial Synthesis of Multivalent Ligands
Combinatorial methods offer a new approach to the
synthesis of multivalent ligands. Combinatorial and diversity-
oriented synthesis of monovalent molecules has facilitated the
discovery of low-molecular-weight ligands that are optimally
designed to bind to a target receptor.[168–173] Similarly, libraries
of multivalent ligands might be expected to contain com-
pounds that possess diverse activities.[119–121, 166,167, 174]
The technical hurdles to overcome in the synthesis of
small-molecule libraries are different from those encountered
with multivalent ligand libraries. For example, multivalent
ligands bearing different REs can have different physical
properties; therefore, they will require different purification
methods. Combinatorial approaches to multivalent ligand
synthesis are in their infancy, and only a few synthetic
strategies for generating diverse multivalent ligands have
been described.[119–121,153, 166,167, 174] Future advances in synthetic
methods and purification technologies will be instrumental in
providing multivalent materials with a broad range of
architectural diversity.
3.4.Mechanisms of Multivalent Ligand Binding
Multivalent ligands can bind receptors in ways that are
inaccessible to monovalent compounds (Figure 5).[100,115, 175]
For example, a ligand with multiple copies of an RE can
bind to multiple binding sites on a single oligomeric receptor
(examples of such receptors are immunoglobulins and some
lectins). The cost for translational entropy is paid with the first
receptor–ligand contact, and subsequent binding interactions
proceed without additional penalties in translational
entropy.[176] Excellent examples of this chelation binding
mode are presented in recent studies directed at devising
multivalent inhibitors of pentavalent toxins.[177–179] Similarly,
certain receptors possess binding subsites in addition to their
primary site of interaction. Unlike monovalent ligands, which
can only access subsites adjacent to their primary binding
pocket, multivalent ligands may gain binding energy from
contacting more remote secondary sites.[180] Either an RE or
another component of the scaffold can contact these subsites.
In situations where the multivalent ligand occupies more than
one binding site—whether it is a subsite or a primary site
within an oligomeric receptor—the ligand typically will bind
with a high functional affinity.[181] Another mechanism by
which a multivalent ligand can act is through steric stabiliza-
tion: The steric bulk of the multivalent ligand may preclude
the engagement of a bound receptor with an opposing viral
particle or cell.[182] This aspect of multivalent ligand activity is
particularly relevant for inhibitors of binding interactions at
the cellular or viral surface. All these binding modes together
are unique to multivalent ligands and have led to numerous
applications of these reagents as inhibitors of macromolecular
interactions.
Multivalent ligands do not have to inhibit a process, they
can act as activators of signal transduction. Multivalent
ligands can bind avidly to multiple receptors on the cell





Figure 5. Receptor binding mechanisms that are unique to multivalent
ligands.
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the two-dimensional diffusion of receptors. The multivalent
ligands can activate signaling pathways if they can cluster
signaling receptors (Figure 5c). It is this mechanism, which is
uniquely available to multivalent ligands, that is the focus of
the remainder of this Review.
We have outlined the three major concepts that are
critical for the application of multivalent ligands as probes of
signal transduction: 1) signal transduction cascades are medi-
ated by receptor–receptor interactions, and promoting recep-
tor assembly is critical for signaling (Figure 3). 2) Multivalent
ligands can interact with the target receptors through multiple
binding modes (Figure 5). 3) The structure of a multivalent
ligand will determine the favored binding modes (Figure 4).
Thus, the structure of the ligand can be optimized to elicit the
desired biological response.[84] In the next sections, we provide
some examples that illustrate the utility of multivalent ligands
as mechanistic probes.
4. Using Multivalent Ligands to Gain Insight into
Receptor Function
The binding of a multivalent ligand to a cell surface can
assemble a multiprotein complex with distinct features. The
valency of the ligand, the orientation of REs, and the stability
of the interaction can be used to control features of the
complex: its stoichiometric composition, its size, the orienta-
tion of the receptors within it, and the lifetime of the complex.
Thus, a multivalent ligand can have a marked influence on the
output response of a signaling cascade. The following
examples describe how specific multivalent ligands can be
used to analyze signaling.
4.1. Receptor Proximity
The binding of multivalent ligands can
result in clustering of the receptors in the
membrane.[84] Here, we discuss some of the
many examples in which the ability of multi-
valent ligands to promote clustering has been
used to reveal aspects of receptor function.
4.1.1. Integrins
Integrins are cell-surface receptors that
mediate cell adhesion; they also play a central
role in the focal adhesion signaling com-
plex.[24, 183–185] Integrin function is important in
multicellular organisms, and targeted deletion
of integrin subunits can strongly impair tissue
formation.[186] Given their fundamental phys-
iological roles, it is not surpising that integrin-
mediated adhesion and signaling events are
carefully regulated.
A key feature of integrins is their ability to
switch between low- and high-affinity binding
modes.[187] These two modes are thought to
allow rapid and reversible adjustments of the
strength of the cell adhesion. This switch likely involves
changes in the integrin conformation, proximity, or both.[188]
Integrins are proposed to adopt at least two conformational
states: a bent inactive state and an extended active state.[187] In
addition, they can undergo changes in receptor proximity,
which can be induced either by interaction with a ligand (an
“outside-in” change) or by cellular activation (an “inside-out”
change). Although there is evidence that both proximity and
conformation influence signaling and adhesive strength, more
specific and useful therapeutics may result from a deeper
understanding of the relative contributions of these mecha-
nisms. Insight into the influence of the receptor proximity in
focal adhesion function is emerging from experiments with
synthetic multivalent ligands.
One group of synthetic ligands used to probe integrin
clustering are chemical inducers of dimerization (CIDs).
CIDs are low-molecular-weight, cell-permeable, divalent
ligands that can mediate the clustering of two recep-
tors.[4,116, 189–191] A key feature of CIDs is that they can
oligomerize receptors fused to a specific ligand-binding
protein (Figure 6). This strategy first utilized fusions to
FKBP, a protein that binds to the immunosuppressant
FK506.[189] FK506 is a low-molecular-weight drug that can
be functionalized and converted into the dimer FK1012,
which is capable of dimerizing FKBP. FKBP fusion proteins
can be transfected or otherwise introduced into cells, thus
permitting examination of the functional consequences of
FK1012-mediated dimerization of the target fusion proteins.
Ligand addition can induce formation of higher order
assemblies if multiple copies of FKBP are fused to the
target protein of interest.[192] Such strategies have been











































Figure 6. Depiction of the intracellular-mediated alteration of receptor proximity by CID. A
receptor fused to a binding protein is expressed in a target cell. Addition of a small-molecule
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agents that avoid endogenous proteins (for example, FKBP)
and specifically target engineered fusion proteins.[192–194]
Both the proximity and conformation of the integrin
contribute to the change in the binding affinity. A CID
strategy was employed to dissect the role of conformational
change from that of receptor proximity.[195] A gene encoding
two copies of FKBP in tandem was fused to that encoding
aIIb; the latter is a part of the integrin complex aIIb-b3. The
addition of the dimerization agent AP1510 elicits integrin
clustering in cells producing the fusion protein. If proximity
alone is important for the switch between low and high
affinity, one would expect that AP1510 would fully replace
the need for a natural binding partner. As a measure of the
switch to the high-affinity binding mode, an antibody (PAC1)
was used that binds specifically to the high-affinity form of the
integrin. Addition of the FKBP dimerization agent AP1510 to
the cells resulted in a dose-dependent increase in the binding
of PAC1. To investigate the role of the conformational change
of the receptor, these authors used the monovalent antibody
fragment LIBS that binds and potently activates integrins.
The increase in binding observed in the presence of AP1510
was modest; the effect from LIBS treatment was more
dramatic. These studies with CIDs indicate that, although
there is a contribution from receptor proximity, other factors,
such as adopting the high-affinity conformational state,
contribute significantly to integrin-mediated cell adhesion.
Integrins are cell-surface proteins that are not only
involved in adhesion but also in intracellular signaling.
Signaling from integrins involves the activation of multiple
pathways. As is the case for most complex signaling systems,
efforts to deconvolute the contributions of each pathway are
ongoing. The two kinases Syk and FAK are implicated in
transducing signals through different pathways in integrin
signaling. The formation of integrin clusters may favor
information transfer through one of these pathways (Syk or
FAK) over others. To test this hypothesis, the role of receptor
proximity in signaling by Syk and FAK was explored with the
dimeric ligand AP1510. When cells were treated with AP1510
alone to cluster the integrin aIIb-b3, an increase in tyrosine
phosphorylation by Syk was observed. The requirements for
activation of FAK, however, include both the receptor in the
high-affinity state (treatment with LIBS) and oligomerization
(treatment with AP1510). These results demonstrate the
complex interplay between signaling, adhesion, and cellular
response that can be achieved by changes in integrin
occupancy, proximity, or both. These investigations illustrate
the utility of the CID strategy for deconvoluting these
contributions. One minor disadvantage of the CID approach,
however, is that the cells need to be genetically engineered to
express the fusion proteins.
Multivalent surfaces can be used to probe integrin
function directly. Integrins can facilitate cell adhesion to
extracellular matrix components as well as other cells.[185,196]
The extracellular matrix, a naturally occurring multivalent
display, may therefore also influence integrin activity.[197] In
one study, surfaces were modified with monovalent fibrino-
gen or monovalent fibrin for use in cell-adhesion studies.[198]
Lymphoblastoid B cells were allowed to adhere to the coated
microtiter wells (Figure 7 A). The multivalent fibrin was able
to support cell adhesion but unactivated cells did not adhere
to immobilized monovalent fibrinogen.
In a series of related experiments adenovirus PB, a ligand
specific for the integrin avb3, was coated in wells in either its
monomeric or pentameric form (Figure 7b). As in the fibrin
experiment, the B cells attached selectively to the wells
coated with multivalent ligand. To understand the mecha-
nisms responsible for the differences in binding, the number
of possible integrin binding sites in the wells displaying
monomeric (800 sitesmm2) or pentameric ligand
(125 sites mm2) was determined by radioimmunoassay.
Although it had sixfold fewer sites per mm2, the surface
displaying the pentameric integrin ligand was more adhesive.
These results suggest that the local arrangement of binding
sites, and not the overall number of sites, is critical for
integrin-mediated adhesion.
These results are supported by additional data that
indicate local RE density is important for the adhesion
strength of integrin.[127] Maheshwari et al. used star polymers
that display variable numbers of copies of the minimal
integrin ligand YGRGD to investigate the impact of binding-
site density on integrin-mediated cell migration and adhesion
of avb3-bearing cells. The integrin avb3 binds RGD sequences,
and surfaces with more YGRGD were more effective at
interacting with cells (Figure 7B). Interestingly, however,






































Figure 7. The density of REs presented influences the adhesion of cells
to surfaces bearing integrin ligands. A) Surfaces coated with multi-
valent ligands have a greater functional affinity for B cells. B) Star
polymers are depicted that display variable copies of the pentapeptide
YGRGD (an integrin-binding RE). The relative potency of each surface
is indicated by the number of cells bound.
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densities were compared, those with closely packed REs were
more efficient at mediating cell migration and adhesion.
These results suggest that clustering of the integrins improves
their adhesive strength, probably through both enhanced
functional affinity for the ligand and by activation of the
signaling pathways.
These experiments with synthetic multivalent surfaces
have highlighted a role for receptor proximity in integrin
function. These studies also provide information about the
most effective types of natural integrin ligands. Unfortu-
nately, these multivalent surfaces cannot be used to explore
integrin function in living organisms. Experiments utilizing
soluble multivalent ligands could be used to investigate the
consequences of integrin clustering in physiological settings.
4.1.2. G-Protein-Coupled Receptors
GPCRs are one of the largest families of mammalian cell-
surface receptors. They participate in many important phys-
iological processes. Their significance is underscored by their
importance to medicine: over 50% of therapeutics on the
market act through GPCRs.[199] Mounting evidence implicates
GPCR homo- and heterodimerization in the regulation of
signaling from these receptors.[117, 200] Therefore, it would be
valuable to elucidate the contribution of GPCR oligomeriza-
tion to understand GPCR signaling and to exert control over
it. The role of the ligand in modulating the clustering of
GPCRs is unknown, but experiments using synthetic multi-
valent ligands are beginning to address this issue.
Low-molecular-weight divalent ligands have been used to
assess the consequences of receptor dimeriza-
tion.[103, 117,186, 201–207] An illustration of this approach is the
use of the dimer of a GPCR ligand to activate neutrophil
chemotaxis.[208] Neutrophils are attracted to sites of bacterial
infection by by-products of bacterial protein synthesis, such as
N-formylmethionine-containing peptide fragments. Perhaps
the most widely studied neutrophil chemoeffector is N-
formylmethionine-leucine-phenylalanine (fMLF), which is
recognized by the formyl peptide receptor (FPR)—a
GPCR. Dimers presenting two copies of fMLF were, there-
fore, employed to explore the role of receptor proximity in
the regulation of FPR signaling.
Mono-, di-, and triethylene glycol-linked dimers of fMLF
were generated by coupling a linker to the C terminus of the
peptide. The monoethylene glycol dimer would not be
expected to be capable of dimerizing the FPR; consequently,
any enhanced chemotactic activity relative to fMLF is likely
due to an increase in avidity. In contrast, the authors suggest
that the triethylene glycol linked dimer may facilitate
dimerization of the receptor, although the linker length
required to simultaneously occupy two copies of the FPR is
not known. The authors generated a series of divalent ligands,
hoping that those with longer linkers might dimerize the FPR.
Two assays were used to explore FPR function: chemo-
taxis and superoxide production.[208] Neutrophils are recruited
in vivo to the location of the invading pathogen through
chemotaxis; the release of superoxide serves a killing role.
These two cellular responses must occur with strict spatial and
temporal control to minimize damage to healthy tissue.
Specifically, chemotaxis towards a site of bacterial infection
must precede superoxide formation or the neutrophils could
prematurely release toxic oxygen species. Both of these
responses can be elicited in response to ligand binding to
FPR. It is important, therefore, to understand what factors
influence the triggering of these distinct cellular responses.
The synthetic dimers were added to cells expressing FPR,
and the chemotaxis and superoxide levels were monitored.
The triethylene glycol linked dimer was the most active
chemoattractant, while the monoethylene glycol dimer eli-
cited the highest level of superoxide production. Although
FPR dimerization was not tested directly, these results suggest
that dimerization of the receptor may influence chemotactic
responses. The increased ability of the monoethylene glycol
dimer to elicit superoxide release was attributed to it having
higher affinity for the FPR. Although the specific mechanisms
of action of these divalent agents were not probed further,
these initial results suggest that synthetic multivalent ligands
will be useful in illuminating the role of receptor clustering in
GPCR signaling in general, and chemotactic signaling in
neutrophils in particular.
Receptor heterooligomerization can provide a means of
integrating information from multiple pathways into a
coherent cellular response. The consequences of GPCR
heterodimer formation have been probed by creating hetero-
dimeric ligands.[103] This approach was taken to study the
effects of coclustering a GPCR that responds to enkephalin
with one that is activated by neurotensin. Both natural ligands
are important regulatory neuropeptides that function as
synergistic activators of GPCR signaling.[209] The goal of the
studies was to determine whether there might be a direct
potentiation of signal through assembly of a heteroligomeric
GPCR complex.
Cells expressing both receptors were treated with neuro-
tensin, a mixture of neurotensin and enkephalin, or a
difunctional neurotensin–enkephalin conjugate[209] The cyto-
solic cyclic GMP (cGMP) concentration was measured at a
variety of ligand doses. Only a subtle increase in cGMP
production was observed when both hormones were added
separately. In contrast, the covalent heterodimer was a potent
inducer. These data suggest that the forced proximity of the
two receptors is the primary cause for the increased level of
cGMP. As in the previous example, however, direct data in
support of heterodimerization are lacking.
Further experimentation with ligands bearing higher
valencies or more diverse architectures may afford more
definitive insights into the effects of receptor proximity on
GPCR-mediated signaling. It will be especially useful to
couple signaling studies with those that address the influence
of ligands on GPCR assembly. Since so many drugs target
GPCRs, these investigations may facilitate the design of a new
generation of therapeutics.[210]
4.1.3. T-Cell Receptors
T lymphocytes are key mediators of mammalian immun-
ity.[13, 22,78, 211] These cells recognize foreign antigens through
their T-cell receptors (TCRs). Binding at T-cell receptors can
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of tumor cells, pathogens, and virally infected cells. As
discussed in Section 1, when T cells encounter antigen-
presenting cells, an immune synapse can form at the cell–
cell interface. This immune synapse, which contains the TCR
as well as other co-receptors and signaling components,
possesses exquisite organization.[76]
There is evidence that changes in the organization of the
TCR and other signaling components are important for T-cell
activation; however, the contribution of various factors to
TCR signaling remains unclear. Despite the large body of
literature on TCR organization and signaling, questions
remain concerning the molecular details of TCR function.
For example, it is uncertain as to whether the dimerization of
two TCRs is sufficient stimulus for T-cell activation or
whether TCR oligomerization is required. The role of
simple monovalent ligation of individual TCRs is also
unknown.[212] The purpose of the synapse is unclear if
individual or small groups of TCRs can activate signaling.
Multivalent ligands will undoubtedly play prominent roles in
addressing these fundamental issues.
One strategy for studying TCR function uses multivalent
protein conjugates which are formed from the high-affinity
interaction between biotin and the tetravalent protein
streptavidin.[213] The four identical biotin-binding sites of
streptavidin each bind with a dissociation constant of 1015m ;
therefore, biotinylated recognition elements can be readily
displayed from a streptavidin scaffold. Since streptavidin is
tetravalent, multivalent complexes can be generated that
present 1, 2, 3, or 4 recognition epitopes per scaffold
(Figure 8). Davis, McConnell, and co-workers developed
streptavidin as a scaffold for the presentation of peptide-
loaded major histocompatibility complexes (MHCs).[213] Since
peptide-loaded MHCs can serve as ligands for the TCR,
streptavidin-bound biotinylated MHC complexes can bind (in
principle) up to four TCRs.
To generate these multivalent presentations, a peptide
derived from moth cytochrome c (MCC) was added to the
MHC. The resulting MCC–MHC complex was singly biotin-
ylated and mixed with streptavidin; this procedure should
yield a tetravalent complex that can bind the TCR (Figure 8).
The amount of active MHC complex in the assembly reaction
was varied to favor formation of mono-, di-, tri-, or tetrameric
structures. Biotinylated MHC that lacks MCC was also
produced, and these proteins, which cannot bind the TCR,
were added to occupy the remaining streptavidin sites. A
complex displaying four unloaded MHCs, which does not
display foreign antigen, served as a control.
To test the effects of the assemblies on T-cell activation,
decreases in extracellular pH values and increases in the
concentration of intracellular Ca2+ were measured. In both
cases, the tetramer was the only ligand to elicit a significant
increase in activity. Although effects arising from changes in
binding kinetics cannot be ruled out, these experimental
results suggest that changes in TCR proximity influence T-cell
activation. Similar results were obtained using chemically
defined peptide-based multivalent ligands, although a dimeric
ligand was sufficient to activate TCR signaling.[214,215] These
data taken together suggest that valency is an important
feature of natural TCR ligands and that receptor proximity is
important for the amplification of TCR-mediated signals.
Factors other than TCR ligation also contribute to
activation and signal modulation. Indeed, numerous co-
receptors serve to positively or negatively modulate the
activation signal. One limitation of using streptavidin-based
scaffolds is that it is difficult to incorporate multiple REs that
can engage co-receptors and TCRs simultaneously. Thus,
scaffolds that can be functionalized to present multiple types
of REs have been employed.
A variety of beads and surfaces have been used as
multivalent displays to explore T-cell signaling.[9,129, 216–218] In
this way, a study addressing the mechanism by which T-cell
responses are enhanced by the co-receptor CD28 was under-
taken.[87] Ligand binding to the TCR is necessary and
sufficient for activation of T cells; however, co-stimulation
of CD28 yields a more potent response. To determine the
mechanism for enhanced signaling, beads were used to mimic
the physical size of the surface of an antigen-presenting cell
(APC), which presents ligands on its cell surface for the TCR
and CD28.
Latex beads were modified to assess the consequences of
simultaneous binding to receptors. Specifically, they were
designed to cocluster the TCR and CD28: an antibody that
recognizes the TCR and another that binds the co-receptor
CD28 was attached. The beads were tested for their ability to
induce cell proliferation, which occurs upon lymphocyte
activation. If T-cell activation requires simultaneous binding
of both the TCR and CD28, only the beads displaying REs for
both receptors should activate the cells. Beads displaying only
the TCR clustering element (anti-TCR) did not promote T-
cell proliferation. In contrast, beads displaying both anti-TCR
and anti-CD28 were potent activators of proliferation.
One explanation for the data is that simultaneous binding
of CD28 and TCR promotes the co-localization of these
receptors to a region of the membrane termed a lipid
microdomain. It has been suggested that lipid microdomains
concentrate signaling components and facilitate formation of
mature signaling complexes. Support for a role for micro-














Figure 8. Schematic representation of streptavidin-MHC-MCC com-
plexes. Left: Four complexes with one, two, three, or four biotinylated
MHC-MCC moieties; right: a model for the activation of TCRs by
multivalent engagement by the highest valency ligand.
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of a fluorescent marker of lipid rafts (fluorescein-labeled
cholera toxin B subunit) into a dense fluorescent patch at the
point of contact between the bead and the T cell. These
results demonstrate that co-stimulation of the TCR and co-
receptors can modify their distribution on the cell surface,
which may modulate immune responses. An important caveat
to these experiments, however, is that the REs on a bead-
based multivalent ligand are immobilized. Thus, unlike cell-
surface REs, the REs attached to the bead cannot undergo
rearrangement. However, similar results were obtained when
an antigen-presenting cell was used as a natural “ligand”. This
comparison suggests that the RE-decorated bead effectively
mimics some aspects of an antigen-presenting cell.[219] Thus, a
role for the CD28 co-receptor in regulating receptor prox-
imity and immune function was implicated from studies using
functionalized beads as multivalent ligands.
4.1.4. Bacterial Chemoreceptors
Bacteria must migrate towards nutrients and away from
toxins to survive. Bacterial chemotaxis is driven by a well-
characterized signaling pathway that is responsible for the
detection of these nutrients and toxins.[220–222] Five types of
membrane-bound chemoreceptors (MCPs) mediate chemo-
taxis in Escherichia coli. Each MCP type is responsible for
detecting and mediating chemotaxis towards a subset of small
molecules or other stimuli. Bacteria require integration of
signals from multiple stimuli into a coherent response to
initiate appropriate locomotion. Moreover, responses are
mounted against stimuli at very low concentrations, which
requires a significant level of signal amplification.[223–225]
The mechanism used by bacteria to amplify and integrate
chemotactic signals has long been debated. One recent
hypothesis is that signal amplification is achieved through
interreceptor communication.[26, 54, 60,226, 227] Interestingly, the
MCPs are organized within the cell: They are concentrated at
the poles of Escherichia coli and other bacterial species.[39,228]
This organization of chemoreceptors into an array has been
proposed to be important in signal transduction. Recent
experiments using synthetic multivalent ligands and other
approaches support such a view; they suggest that communi-
cation between homologous and heterologous MCPs within
the chemoreceptor array is responsible for chemotactic
responses.[46, 54,60, 62, 229–231]
The first goal was to generate multivalent attractants that
could cluster the chemoreceptors. ROMP was used to
synthesize multivalent ligands that display chemotactic car-
bohydrate residues in sufficient valency (ca. 25 monomer
units) to mediate MCP clustering, as shown by microscopy.
This change in receptor proximity influenced signaling
through the MCPs: ligands capable of clustering MCPs were
also potent activators of chemotaxis (Figure 9). It was shown
by using a fluorescent probe that galactose-bearing multi-
valent ligands cluster the galactose-sensing receptor Trg.
Surprisingly, they also cluster the serine-sensing receptor Tsr.
Tsr does not bind galactose; its presence in the cluster
suggests that chemoreceptor–chemoreceptor interactions
bring it into the cluster. These data indicate that there are
interactions between different types of chemoreceptors.
Evidence in support of the functional significance of
chemoreceptor–chemoreceptor interactions was obtained by
examining the effects of receptor clustering on signal output.
Specifically, a multivalent galactose derivative was introduced
to cluster the chemoreceptors. When the bacteria had adapted
to the multivalent attractant, the monovalent attractant serine
was added. Under these conditions the chemotactic response
to serine was potentiated by 100- to 1000-fold. This result
indicates that heterologous MCPs communicate so as to
amplify and integrate chemotactic signals. The proximity of
multiple types of receptors is critical for signal amplification.
Thus, a single receptor is not all that is needed to sense a
particular compound—all chemoreceptor types contribute to
proper sensing and signal amplification.
The application of multivalent chemoattractants to exam-
ine chemoreceptor proximity in chemotaxis illustrates their
power: They can be used to explore signal transduction even
when receptor dimerization is known to be required. Changes
in receptor organization had not been implicated in chemo-
tactic signal transduction: the role of receptor organization
might have been overlooked because the known chemo-
attractants are monomeric, and the MCPs are dimeric in the
absence of ligands. Nevertheless, studies indicate that changes
in MCP proximity influence signal amplification, and evi-
dence supporting such a model was obtained using multi-
valent ligands. Moreover, the use of these ligands did not
require genetic manipulation of the bacteria; thus, the
behavioral response elicited by the multivalent ligand could
be directly analyzed under physiological conditions and in
wild-type genetic backgrounds. These results underscore that
soluble, structurally defined multivalent ligands are valuable
probes.
4.2. Receptor Orientation
Many cell-surface receptors possess domains with intrinsic
enzymatic activity, while some interact with proteins with
catalytic domains. The substrates of these enzymatic activities














Figure 9. Investigation of receptor proximity effects in bacterial chemo-
taxis by using synthetic multivalent polymers. Addition of a multivalent
ligand with sufficient valency can induce the reorganization of MCPs
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the active site of the receptor-associated enzyme as well as the
substrate may influence the amount of product generated;
this enzymatic efficiency, in turn, will influence signal trans-
duction.[225, 229, 230,232] It is often unclear whether the activity of
an assembled signaling complex is the result of a specific
orientation of receptors within the complex or simply the
localization of signaling components.[233] Since multivalent
ligands can organize receptors into specific orientations, they
have the potential to serve as tools for investigating the role of
protein orientation in signaling.
4.2.1. G-Protein-Coupled Receptors (GPCRs)
One key feature of multivalent ligands is that they can
occupy multiple binding sites on a single receptor and thereby
exploit the chelate effect (Figure 5a).[176] Multivalent ligands
that use this binding mode can interact with high functional
affinities, and is an important determinant of agonist or
antagonist potency. In a recent example, a low-molecular-
weight dimer was constructed that can bind simultaneously to
two sites on the corticotrophin-releasing factor receptor
(CRFR-1). CRFR-1 is a GPCR that is a key regulator of
adrenocorticotropic hormone (for example, testosterone)
release during the stress response.[234]
A series of dimers was generated, in which different
orientations of the REs were controlled by using helical and
rigid linkers. The addition of these dimers to cells expressing
CRFR-1 resulted in the release of testosterone. Potent
activity was elicited by the dimers that maintained a trans
orientation between the terminal REs. Ligands that did not
maintain this orientation were tenfold less effective at causing
testosterone release. The experiments conducted do not
eliminate the possibility that the observed differences arise
from ligand-induced changes in receptor oligomerization, but
the results suggest that the orientation of REs can influence
receptor activation.[117, 235]
4.2.2. ZAP-70
Chemical synthesis can be used to create ligands to probe
the role of protein orientation in assembled signaling com-
plexes. In the previous example, the relative orientation of the
binding moieties within a multivalent ligand influence its
ability to elicit signaling through a target receptor. When a
multivalent ligand acts by clustering receptors, however, the
geometric constraints on the binding epitopes might be
relaxed. In the few examples studied to date, the localization
of receptors to a signaling complex is often more important
than their specific orientation within the complex.[233,236] The
ability of dimeric ligands to activate signaling by ZAP-70 is
consistent with this view and highlights that different RE
orientations often give rise to only subtle effects.[107]
ZAP-70 is a kinase whose function is required for the
varied signaling functions of the T cell. If the orientation of
ZAP-70 is important for its function, multivalent ligands that
control its orientation should possess varying abilities to elicit
T-cell activation. To this end, a series of small-molecule
dimeric ligands was generated; each possessed conformation-
ally restricted linkers between the two identical REs. The
activity of this series was assessed by adding CIDs to cells
encoding a membrane-docking protein (three copies of FKBP
fused to a myristoylation domain of v-Src) and a ZAP-70–
FKBP fusion protein (Figure 10). Presumably, these CIDs can
bind and cluster the fusion proteins, thereby recruiting ZAP-
70 to the membrane. All of the synthetic CIDs mediated
ZAP-70 recruitment and all activated signaling. While large
changes in orientation may influence ZAP-70 signaling, the
presumed changes in the orientation afforded by the CIDs
had little effect.
The difference in the results of the CRFR-1 versus the
ZAP-70 studies suggests a plasticity in the assembly of
signaling complexes: For signal activation, the REs of dimeric
ligands that occupy subsites within a receptor must be more
carefully aligned than those that act by inducing changes in
receptor proximity. Interestingly, these findings are consistent
with studies in which fusion proteins have been used to test
whether different assemblies of signaling domains influence
output.[233,236] As with the ZAP-70 investigations, the orienta-
tion of different signaling domains was much less important
than their recruitment to a signaling complex. It will be
interesting to explore the generality of these findings further.
4.3. Composition of Receptor Clusters
The number of receptors in a complex can influence its
































































































































Figure 10. Investigation of the influence of the orientation of ZAP-70
on its kinase function by a CID strategy. The chemical structures of
three dimerization agents FK1012, FK1012H2, and FK1012Z are
shown. These dimers present REs in three distinct relative orienta-
tions, but their abilities to induce ZAP-70 activity were similar.
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sensitive to the number of receptors in a complex; the
functional affinity of the array is expected to be directly
related to the number of receptor–ligand complexes
formed.[100] Signal transduction processes also may be sensi-
tive to the number of receptors in the complex; however, it
can be difficult to determine the quantitative role of receptor
composition in signaling. Multivalent ligands can be gener-
ated that vary in the density and valency of REs so as to
investigate either cell adhesion or cell signaling. These
ligands, therefore, may have the ability to generate specific
clusters of receptors that vary in the number of proteins
included. This strategy has been utilized to investigate the
role of composition for receptor function.
4.3.1. B-Cell-Antigen Receptor
The B-cell-antigen receptor (BCR) is a complex com-
prised of proteins involved in the recognition of antigens and
the generation of antibodies during acquired immune
responses.[23, 85,237] The activation of BCR-mediated functions
must be strictly regulated, since inappropriate activation can
cause autoimmune disease. Understanding the minimal
requirements for BCR-mediated activity is therefore critical.
Synthetic multivalent ligands have played key roles in
investigating the importance of antigen stoichiometry in the
activation of this system.
Pioneering work by Dintzis et al. and others in the field of
BCR signaling in the 1970s and 1980s utilized synthetic
multivalent ligands to explore the role of valency in B-cell
responses.[238–242] The binding of a multivalent antigen to the
B-cell receptors (BCRs) can activate B-cell signaling. A series
of multivalent ligands were generated using polyacrylamide,
dextran, carboxymethylcellulose, and polyvinyl alcohol as
scaffolds to test how the valency of T-cell-independent
antigens influences antibody production.[243] These ligands
were injected into mice, and the efficiency of antibody
production was measured. In every case, irrespective of the
scaffold structure or the amount of polymer branching, the
immunogenicity of the ligands strictly depended on the RE
valency. From these data, the authors hypothesize that the
number of BCRs included in a cluster is a principle
determinant of function. Moreover, they propose that occu-
pation of approximately 12 BCRs is required for B-cell
activation. There are many steps in this complex system
between B-cell activation and antibody production. These
investigations highlight, however, the power of synthetic
multivalent ligands for answering questions of fundamental
biological importance.
4.3.2. L-Selectin
Leukocyte migration from the blood to lymphatic tissues
is dependent on the function of L-selectin; L-selectin also
mediates leukocyte recruitment to sites of inflammation.[244]
L-selectin is displayed on the surface of leukocytes, and it
typically localizes to patches at the tips of the cellular
microvilli (Figure 11).[237,241–246] The natural ligands for L-
selectin are glycoproteins displayed on the endothelium of the
blood vessel.[247] The binding of L-selectin to these ligands
slows the progress of cells through the blood vessels and
allows tight adherence of the leukocyte to the endothelium.
Physiological L-selectin ligands typically present multiple
copies of derivatives of the sulfated sialyl Lewis x antigen
(sLex); synthetic multivalent ligands that display these and
related carbohydrate epitopes have been shown to be
effective selectin ligands.[248–253] Multivalency, therefore, may
be an important determinant of L-selectin function in vivo.
Experiments using synthetic multivalent ligands have started
to reveal the importance of multivalency and stoichiometry of
selectin–ligand clusters for L-selectin recognition.
The role of the receptor composition in regulating the
adhesion function of L-selectin was investigated using syn-
thetic multivalent ligands derived from ROMP.[254] The
polymers were specifically end-labeled with a single fluoro-
Figure 11. Multivalent ligands for L-selectin mimic cell-surface glycoproteins. A) L-selectin expressed on lymphocytes binds to glycoproteins on the
endothelium. This interaction slows lymphocyte progression through the vessel and triggers proteolytic release of L-selectin. B) Multivalent
polymers displaying sulfated carbohydrates also bind multiple copies of L-selectin, which leads to receptor clustering and proteolytic shedding.
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phore to visualize binding and to determine how many copies
of a multivalent ligand bind L-selectin-positive cells.[255] It was
found that the number of copies of L-selectin that bind to a
multivalent sulfated carbohydrate derivative depends on its
valency (Figure 11).[254] A related observation is that the
functional affinity of a ligand for cells displaying L-selectin is
directly related to its valency. Increasing the valency from 35
monomer units to 150 resulted in an increase in the relative
ratio from 1.1 to nearly 5 copies of L-selectin. The functional
affinity of the interaction improved 10-fold. These results
suggest that the adhesive strength of L-selectin is related to
the stoichiometry of the selectin–ligand complex.
Intriguingly, these polymers not only bind L-selectin but
also promote its proteolytic release, or shedding, from the cell
surface.[256,257] It appears that cell signaling is important for
triggering the release of L-selectin:[165,258] it is possible that
clustering L-selectin activates the signaling cascade that leads
to its cleavage; or perhaps physiological L-selectin ligands
also influence L-selectin levels in vivo. These results taken
together suggest that the stoichiometry of L-selectin–ligand
interactions is an important determinant of both the adhesive
and signaling functions of this protein.
5. Summary and Outlook
Cell-surface receptors mediate the essential tasks of cell
adhesion and signaling. In these roles receptors are rarely left
to function as isolated entities. Rather, they collaborate as
constituents of higher order macromolecular assemblies.
Understanding the mechanisms underlying the function of
these assemblies is critical. Multivalent ligands can serve as
powerful tools for the deconvolution of complex multirecep-
tor networks. The use of synthetic multivalent ligands is
complementary to other approaches; therefore, they provide
the means to address important new questions.
In addition to utility as agents for examining receptor
function, synthetic multivalent ligands have potential appli-
cations in the treatment of disease. Multivalent ligands can
participate in binding mechanisms that are not available to
small molecules. For example, Whitesides, Collier, and co-
workers took advantage of this unique aspect of multivalent
ligands to generate potent polyacrylamide-based multivalent
ligands that function as inhibitors of the anthrax toxin.[259] The
success of these and other[260,261] in vivo applications of
multivalent ligands indicates that they may function not
only as probes of biological processes but even as therapeutic
agents. In addition to their potential uses as inhibitors,
multivalent ligands can mediate the clustering of cell-surface
proteins and thereby function as effectors. While many small-
molecule inhibitors are known, it is typically more difficult to
find small molecules that serve as activators of signal trans-
duction. The ability of multivalent ligands to activate signal
transduction pathways suggest that they may have comple-
mentary therapeutic applications.
Multireceptor complexes are the requisite entities that
convert extracellular stimuli into appropriate cellular
responses. Communication and coordination between recep-
tors provides a means to amplify, integrate, and process
signals. Understanding how these processes occur at a
molecular level is crucial to illuminating the function of
biological systems. While monovalent ligands are powerful
tools for disrupting such complexes, they cannot be used to
examine the importance of the formation of complexes.
Multivalent ligands have the necessary attributes to direct the
formation of multiprotein complexes and/or control the
localization of multiple proteins within the cell. We envision
that such ligands, which can be used in a similar manner as
small molecules for temporal control, will illuminate how
protein assembly and/or protein localization direct cellular
responses.
In this Review, we have provided an overview of some of
the uses of synthetic multivalent ligands as probes. Additional
advances in target-oriented and diversity-oriented syntheses
of multivalent ligands will afford novel compounds that
address increasingly complex biological questions. Such
investigations demand a multidisciplinary approach that
combines chemical and biological concepts to yield, ulti-
mately, a coherent understanding of the molecular mecha-
nisms governing cellular systems.
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